Organization
Clion - CAM Group
1 abstract
Abstract
Neoadjuvant HER2-targeted therapy +/- immunotherapy with pembrolizumab (neoHIP): An open label randomized phase II trial.Org: University of Texas Southwestern Medical Center, Clion - CAM Group, Cedars-Sinai Medical Center, Cancer Care Assoc-TMPN, Cancer Care Associates of York,